SCHEMBL1713805

SCHEMBL1713805

O=C1NC(N2CCOCC2)=NC1=Cc1c[nH]c2ncc(-c3ccccc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK3 O43781 3/20 0.46
▸ PIM1 P11309 3/20 0.46
▸ DYRK1A Q13627 3/20 0.46
▸ DYRK2 Q92630 3/20 0.46
▸ CSNK2A2 P19784 2/20 0.46
▸ CSNK2B P67870 2/20 0.46
▸ CSNK2A1 P68400 2/20 0.46
▸ CSNK2A3 Q8NEV1 2/20 0.46
▸ DYRK1B Q9Y463 2/20 0.46
▸ MAP4K1 Q92918 2/20 0.41
▸ IL2 P60568 1/20 0.41
▸ AXL P30530 6/20 0.41
▸ CDK8 P49336 3/20 0.41
▸ TNIK Q9UKE5 1/20 0.41
▸ PIK3CD O00329 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ PIK3CG P48736 1/20 0.40
▸ GSK3B P49841 2/20 0.40
▸ STK4 Q13043 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713800 1.00 DYRK3 (0.46) DYRK3PIM1DYRK1ADYRK2CSNK2A2
SCHEMBL1713734 0.91 DYRK3 (0.44) DYRK3PIM1DYRK1ADYRK2CSNK2A2
SCHEMBL1713732 0.91 DYRK3 (0.44) DYRK3PIM1DYRK1ADYRK2CSNK2A2
SCHEMBL1714595 0.91 DYRK3 (0.44) DYRK3PIM1DYRK1ADYRK2CSNK2A2
SCHEMBL1714598 0.91 DYRK3 (0.44) DYRK3PIM1DYRK1ADYRK2CSNK2A2
SCHEMBL1713739 0.89 TNIK (0.46) MAP4K1IL2AXLCDK8TNIK
SCHEMBL1713737 0.89 TNIK (0.46) MAP4K1IL2AXLCDK8TNIK
SCHEMBL1713744 0.85 DYRK3 (0.47) DYRK3PIM1DYRK1ADYRK2CSNK2A2
SCHEMBL1713740 0.85 DYRK3 (0.47) DYRK3PIM1DYRK1ADYRK2CSNK2A2
SCHEMBL13676706 0.83 GSK3B (0.47) TNIKPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 — — US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 — — EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 DYRK3 1123/4885PIM1 431/4885DYRK1A 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback